Who are GI265235's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): cabotegravir, CAB, APRETUDE (cabotegravir), Biktarvy 50/200/25 Tab, DTG/3TC, B/FTC/TAF, Atripla (r).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gi265235.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

GI265235 — Competitive Intelligence Brief

GI265235 (GI265235) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIV integrase strand transfer inhibitor (INSTI). Area: Infectious Disease.

marketed HIV integrase strand transfer inhibitor (INSTI) HIV integrase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

GI265235 (GI265235) — ViiV Healthcare. GI265235 is an HIV integrase strand transfer inhibitor that prevents HIV from integrating its genetic material into host cell DNA.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
GI265235 TARGET	GI265235	ViiV Healthcare	marketed	HIV integrase strand transfer inhibitor (INSTI)	HIV integrase
cabotegravir, CAB	cabotegravir, CAB	ViiV Healthcare	marketed	Integrase strand transfer inhibitor (INSTI)	HIV integrase
APRETUDE (cabotegravir)	APRETUDE (cabotegravir)	Massachusetts General Hospital	marketed	Integrase strand transfer inhibitor (INSTI)	HIV integrase
Biktarvy 50/200/25 Tab	Biktarvy 50/200/25 Tab	Radboud University Medical Center	marketed	Antiretroviral combination (integrase inhibitor + nucleotide/nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
DTG/3TC	DTG/3TC	University of Nairobi	marketed	Antiretroviral combination (integrase strand transfer inhibitor + nucleoside reverse transcriptase inhibitor)	HIV integrase; HIV reverse transcriptase
B/FTC/TAF	B/FTC/TAF	The University of Texas Health Science Center, Houston	marketed	Antiretroviral combination (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Atripla (r)	Atripla (r)	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Antiretroviral combination (NNRTI + NRTI + NtRTI)	HIV reverse transcriptase, HIV integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIV integrase strand transfer inhibitor (INSTI) class)

ViiV Healthcare · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GI265235 — Competitive Intelligence Brief. https://druglandscape.com/ci/gi265235. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab